Trials / Withdrawn
WithdrawnNCT01226680
A Study Of Tasocitinib In Dry Eye Subjects
A Phase II, Randomized, Double Masked, Parallel Group, Vehicle Controlled, Multiple-Dose Study Of Tasocitinib (CP-690,550) In Subjects With Dry Eye Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease. Both subjective and objective clinical endpoints will be measured for a duration of 12-week treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tasocitinib | 0.005% QD for 12 weeks |
| DRUG | Tasocitinib | 0.003% QD for 12 weeks |
| DRUG | vehicle for Tasocitinib | vehicle QD for 12 weeks |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-10-19
- Completion
- 2012-10-19
- First posted
- 2010-10-22
- Last updated
- 2018-11-29
Source: ClinicalTrials.gov record NCT01226680. Inclusion in this directory is not an endorsement.